Waters launches enhanced HPLC system with user authentication

Published 17/06/2025, 15:06
Waters launches enhanced HPLC system with user authentication

BRUGES, Belgium and MILFORD, Mass. - Waters Corporation (NYSE:WAT), a $20.4 billion market cap leader in analytical instruments with nearly $3 billion in annual revenue, released Alliance iS HPLC System Software version 2.0, featuring user authentication capabilities on its touchscreen interface, the company announced in a press release Tuesday.

The updated software integrates with Empower Software to provide authenticated user access verification, which the company claims will enhance data security and traceability for pharmaceutical laboratories. According to Waters, the system can reduce common user errors by up to 40%.

"Traceability plays an important role in the security and integrity of pharmaceutical data," said James Hallam, Vice President of Liquid Chromatography-Mass Spectrometry at Waters Corporation.

The system provides individual access control with user authentication, ensuring that all actions performed on the device are identifiable and auditable. This feature aims to address regulatory requirements for comprehensive audit trails in pharmaceutical testing.

Waters states that more than 80% of novel drugs have been submitted to regulatory authorities using Empower Software.

The Alliance iS HPLC Platform has also received Accountability, Consistency, and Transparency (ACT) Ecolabels from My Green Lab, recognizing its sustainable manufacturing practices. According to InvestingPro data, Waters maintains strong operational efficiency with a 59% gross margin and has received positive earnings revisions from 13 analysts for the upcoming period.

The new software version will be available beginning August 2025, according to the company’s statement. Waters currently trades at premium multiples relative to peers, suggesting high market expectations for its growth initiatives. For deeper insights into Waters Corporation’s valuation and growth prospects, InvestingPro offers comprehensive analysis with 8 additional ProTips and detailed financial metrics.

In other recent news, Waters Corporation reported its first-quarter earnings for 2025, surpassing analysts’ expectations with an earnings per share of $2.25, compared to the forecasted $2.22. The company also reported revenue of $662 million, exceeding the projected $655.33 million. Waters has raised its full-year EPS guidance, expecting 8-10% growth. The company recently acquired Halo Labs, aiming to enhance its presence in the biologics sector, which contributes significantly to its revenue. Additionally, Waters launched its first line of affinity chromatography columns for biologic drug manufacturing, aligning with its strategic focus on pharmaceutical and biotech manufacturing.

Analyst firm KeyBanc reiterated an Overweight rating on Waters Corp stock, maintaining a price target of $460, while UBS maintained a Neutral rating with a $360 price target. UBS acknowledges Waters Corporation’s positive growth drivers, such as ongoing instrument replacements and strong pricing power, which are expected to help meet its 2025 financial objectives. The company’s management has effectively communicated its growth strategy, counterbalancing potential headwinds like weaker demand from certain sectors. Waters Corporation’s recent strategic initiatives, including the acquisition of Halo Labs, are anticipated to support its growth trajectory and financial targets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.